CURIS Curis Lifesciences Q2 FY26 results (Jul–Sep 2025) and concall
Curis Lifesciences reported strong financial performance for September 2025, with revenue of 2791.01 lakhs and healthy EBITDA and PAT margins of 21.46% and 15.09% respectively. The company is strategically transitioning towards higher-margin own-brand marketing, aiming for 80% contribution within 3-5 years, supported by IPO proceeds for working capital. While this shift is capital-intensive and time-consuming, partnerships like the one with Eurosun in Nigeria are expected to facilitate market entry and growth, despite geopolitical risks impacting some export products.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q1 FY25 | Q2 FY25 | Q4 FY25 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 9 | 16 | 34 | 28 |
| EBITDA | 3 | 4 | 7 | 6 |
| Net profit | 1 | 2 | 4 | 4 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
